Every 10-Q that Anteris Technologies Global Corp. (AVR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AVR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVR filings page.
Anteris Technologies Global Corp. reported continued operating losses as it advances development of its DurAVR® transcatheter heart valve system and global pivotal Trial. Net sales from legacy tissue products were modest at $1.5 million for the six months ended June 30 2026, up 28% year over year, while the business remains primarily R&D-focused.
R&D expenses rose to $40.8 million and selling, general and administrative costs to $15.3 million, driving an operating loss of $55.0 million and a net loss of $51.7 million for the first half of 2026. Cash used in operating activities was $49.5 million. A major equity raise in January 2026, including a public offering and a strategic $90 million private placement with Medtronic, plus an at-the-market facility of up to $250 million, lifted cash, cash equivalents and restricted cash to $260.9 million at June 30 2026.
Clinically, the company expanded its pivotal Trial with U.S. enrollment following IDE approval, secured U.S. Medicare reimbursement eligibility for trial participants, and obtained French regulatory clearance, supporting broader recruitment. Management states existing liquidity should fund operations for at least 12 months, but material weaknesses in internal control over financial reporting remain under remediation.
Anteris Technologies Global Corp. reported a larger quarterly operating loss as it scales development of its DurAVR THV heart valve, but now holds a significantly stronger cash position after major equity financings. For the three months ended March 31, 2026, net sales were $0.5 million, down slightly from $0.6 million a year earlier, reflecting the wind-down of legacy product distribution.
Research and development expense rose to $17.5 million and selling, general and administrative costs to $6.9 million, driving a net loss of $22.9 million compared with $21.9 million in 2025. Other income increased to $1.7 million, mainly from interest on cash.
The company strengthened its balance sheet with a January 2026 underwritten public offering of 40.0 million shares and a 15.7 million-share private placement to Medtronic at $5.75 per share, generating about $320 million in gross proceeds. Cash, cash equivalents and restricted cash rose to $283.2 million from $12.6 million, and stockholders’ equity improved to $278.4 million from a small deficit, despite an accumulated deficit of $393.6 million. Management believes current cash will fund operations for at least 12 months.
Operationally, Anteris advanced its global pivotal Trial for DurAVR THV, supported by FDA IDE approval and, in April 2026, U.S. Medicare reimbursement eligibility under an existing TAVR coverage determination, enabling U.S. site activation and initial patient enrollment in May 2026. The company continues to consolidate a variable interest entity, v2vmedtech, but has elected to terminate its development agreement after quarter-end, incurring a $0.4 million break fee and removing ongoing funding obligations.
Management again disclosed that disclosure controls and procedures were not effective due to previously identified material weaknesses in internal control over financial reporting, although remediation efforts, including enhanced segregation of duties and control documentation, are under way. Anteris remains an emerging growth and smaller reporting company and expects continued losses as it invests heavily in clinical, regulatory, and manufacturing capabilities to pursue FDA Premarket Approval and CE Mark for DurAVR THV.
Anteris Technologies Global Corp. (AVR) reported a third‑quarter net loss and flagged going‑concern uncertainty. Net sales were $429 thousand, while operating loss reached $22.3 million. R&D expense was $16.8 million as the company advanced the DurAVR® transcatheter heart valve program and pivotal PARADIGM Trial preparations. Selling, general and administrative expense was $5.8 million.
The company recorded a net loss after income tax of $22.2 million for the quarter and $65.2 million year‑to‑date. Cash, cash equivalents and restricted cash were $9.1 million as of September 30, 2025, with net cash used in operating activities of $59.3 million for the nine months, leading management to note “substantial doubt” about continuing as a going concern. Stockholders’ equity was $3.7 million.
Subsequent to quarter‑end, Anteris completed a private placement generating approximately $25.2 million in gross proceeds and received key regulatory milestones for its PARADIGM Trial, including the first European clearance in Denmark and FDA approval to initiate the U.S. IDE study. The trial is designed to support a future PMA and parallel CE Mark efforts.
Anteris Technologies Global Corp. (AVR) reported continued development-stage results as it scales toward a pivotal US trial. Net sales were $0.6 million for Q2 2025 and $1.17 million for the six months, while operating investment drove a loss after tax of $42.99 million for the six months ended June 30, 2025. Cash declined to $28.4 million from $70.5 million at year-end 2024 as operating cash outflows totaled $41.0 million in H1 2025.
The company increased R&D spending to $32.8 million for H1 2025 to scale manufacturing and prepare the PARADIGM randomized pivotal trial; 79 sites are qualified for that study. Anteris completed a U.S. IPO and received net proceeds of $80.0 million (including the over-allotment), but management discloses substantial doubt about the company’s ability to continue as a going concern without additional capital.